Notably, citforadenant (an A2AR inhibitor) in combination with atezolizumab (anti-PD-L1) initiated therapeutic response in both patients naïve to immunotherapies and those refractory to prior immunotherapy exposure, highlighting the potential for this combination to reinvigorate anti-tumor immunity (147). This evidence concerns the gene ADORA2A and neoplasm.